Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials

Barry J. Davis | M. Landray | R. Collins | L. Smeeth | M. Pfeffer | S. Yusuf | J. Bosch | J. Varigos | E. Lonn | P. Ridker | G. Hitman | R. Peto | A. Keech | I. Marschner | Mahboob Rahman | M. Sabatine | C. Cannon | H. White | C. Furberg | P. Serruys | A. Neil | N. Sattar | L. Tavazzi | S. Cobb | M. Flather | A. Tonkin | C. Wanner | S. Murphy | E. Braunwald | P. Barter | F. Zannad | J. Wittes | U. Goldbourt | J. Emberson | H. Halls | L. Holland | K. Wilson | C. Baigent | G. Kitas | R. Schmieder | G. Knatterud | R. Clarke | N. Poulter | L. Blackwell | S. Parish | L. Wilhelmsen | S. MacMahon | K. Hovingh | J. Kastelein | J. Armitage | R. Byington | J. Probstfield | J. Jukema | P. Amarenco | S. Trompet | I. Ford | C. Packard | R. Young | P. Sever | J. Simes | E. Banks | A. Maggioni | G. Tognoni | R. Latini | J. Hopewell | P. Weissberg | D. Betteridge | S. Goto | J. Larosa | H. Holdaas | J. Yamaguchi | H. Wedel | M. Franzosi | J. Kjekshus | P. Sleight | J. Shepherd | S. Cobbe | H. Colhoun | B. Dahlöf | K. Davies | K. Welch | L. Moyé | J. Shaw | J. Downs | M. Clearfield | S. Weis | T. Pedersen | E. Spata | A. Roddick | L. Bowman | C. M. Hawkins | J. Wikstrand | S. Pressel | P. Durrington | J. Macfadyen | L. Simpson | A. Kirby | B. Fellström | D. Preiss | B. Mihaylova | E. Barnes | R. Marchioli | W. Herrington | P. Macfarlane | R. Knopp | D. Lucci | Ajay K. Gupta | H. Arashi | S. Kean | M. Blazing | M. Robertson | J. Tobert | C. Newman | V. Krane | Lara M. Simpson | E. Nicolis | C. Reith | J. Fulcher | Patricia Kearney | W. Koenig | J. Rosa | A. Gotto Jr. | Stephen Evans | Stephen W. Wiviott | R. O’Connell | Michael Blastland | D. Gordon | A. Jardine | M. Koren | Charlie H S Harper | Christina Colin Lisa Jonathan Enti Kelly Heather Lisa Kate J Reith Baigent Blackwell Emberson Spata | Jane Colin Elizabeth Lisa Rory Kelly Jonathan Jordan He Armitage Baigent Barnes Blackwell Collins Da | Emily Michael Stephen Robert Peter Janet Banks Blastland Evans Temple Weissberg Wittes | R. Temple | Michael Eugene James Sabina Terje R Marc Harvey Stephen Blazing Braunwald de Lemos Murphy Pedersen P | James de Lemos | Michael John R Antonio Gotto Stephen Clearfield Downs Jr Weis | A. Jr | Bengt Hallvard Alan Terje R Fellström Holdaas Jardine Pedersen | David Barry Curt Richard Sara Jeffrey Mahboob Lara Gordon Davis Furberg Grimm Pressel Probstfield Ra | R. Grimm | Björn Ajay Neil Peter Hans Dahlöf Gupta Poulter Sever Wedel | Stuart Bengt Hallvard Alan Roland Faiez Cobb Fellström Holdaas Jardine Schmieder Zannad | D. J. H. M. P. N. J. G. A. A. Betteridge Colhoun Durrington Fuller Hitman Neil | J. Fuller | Eugene Barry C Morton Lemuel Marc Frank Braunwald Davis Hawkins Moyé Pfeffer Sacks | F. Sacks | John Hans John Kjekshus Wedel Wikstrand | Christoph Vera Wanner Krane | Maria Grazia Roberto Donata Aldo Roberto Enrico B Luigi Franzosi Latini Lucci Maggioni Marchioli Ni | Jackie Eva Salim Bosch Lonn Yusuf | Jane Louise Rory Anthony Martin Sarah Richard Peter Armitage Bowman Collins Keech Landray Parish Pet | John JP Terje R Kastelein Pedersen | Robert Antonio Gotto John JP Wolfgang Jean Paul M Glynn Jr Kastelein Koenig Macfadyen Ridker | R. Glynn | Anthony Stephen Ian John John Andrew Harvey Keech MacMahon Marschner Shaw Simes Tonkin White | Naveed J Wouter Stella Ian Sataar Jukema Trompet Ford | N. Sataar | Eugene Christopher P Sabina Braunwald Cannon Murphy | Rory Jane Louise Sarah Richard Peter Collins Armitage Bowman Parish Peto Sleight | Pierre K Michael Amarenco Welch | John Terje R Lars Kjekshus Pedersen Wilhelmsen | Phlip Antonio Gotto John La John JP James Barter JR Rosa Kastelein Shepherd | Phlip Barter | Stuart Ian Sharon Peter Chris Michele Naveed James Robin Cobbe Ford Kean Macfarlane Packard Robersto | M.J. Roberston | Hiroyuki Robert Robert Marcus Shinya Uri Jemma Kees Patrici Arashi Byington Clarke Flather Goto Gold | Greg Schwartz | Emily Michael Stephen Robert Peter Janet Banks Blastland Evans Temple Weissberg Wittes | Michael John R Antonio Gotto Stephen Clearfield Downs Jr Weis | A. Jr | Bengt Hallvard Alan Terje R Fellström Holdaas Jardine Pedersen | Björn Ajay Neil Peter Hans Dahlöf Gupta Poulter Sever Wedel | Stuart Bengt Hallvard Alan Roland Faiez Cobb Fellström Holdaas Jardine Schmieder Zannad | D. J. H. M. P. N. J. G. A. A. Betteridge Colhoun Durrington Fuller Hitman Neil | Eugene Barry C Morton Lemuel Marc Frank Braunwald Davis Hawkins Moyé Pfeffer Sacks | John Hans John Kjekshus Wedel Wikstrand | Christoph Vera Wanner Krane | Jackie Eva Salim Bosch Lonn Yusuf | John JP Terje R Kastelein Pedersen | Robert Antonio Gotto John JP Wolfgang Jean Paul M Glynn Jr Kastelein Koenig Macfadyen Ridker | Anthony Stephen Ian John John Andrew Harvey Keech MacMahon Marschner Shaw Simes Tonkin White | Naveed J Wouter Stella Ian Sataar Jukema Trompet Ford | Eugene Christopher P Sabina Braunwald Cannon Murphy | Rory Jane Louise Sarah Richard Peter Collins Armitage Bowman Parish Peto Sleight | Pierre K Michael Amarenco Welch | John Terje R Lars Kjekshus Pedersen Wilhelmsen | Phlip Antonio Gotto John La John JP James Barter JR Rosa Kastelein Shepherd | Phlip Barter | G. Schwartz | Robert Glynn | S. Goto | L. Moye | Genell Knatterud (deceased) | Robert H Knopp (deceased) | H. White | D. J. Betteridge (deceased) | John Fuller (deceased) | Hallvard Holdaas (deceased) | John Shaw (deceased) | James Shepherd (deceased) | Peter Sleight (deceased) | Charlie Harper | B. Dahlöf | C. Hawkins | David Gordon | Jean G Macfadyen | C. Harper | Peter Macfarlane

[1]  Cholesterol Treatment Trialists’ Collaboration.  Harmonisation of large-scale, heterogeneous individual participant adverse event data from randomised trials of statin therapy , 2022, Clinical trials.

[2]  A. Khera,et al.  Step‐by‐step diagnosis and management of the nocebo/drucebo effect in statin‐associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP) , 2022, Journal of cachexia, sarcopenia and muscle.

[3]  M. Mazidi,et al.  Prevalence of statin intolerance: a meta-analysis , 2022, European heart journal.

[4]  S. Weller,et al.  Intensity of statin therapy and muscle symptoms: a network meta-analysis of 153 000 patients , 2021, BMJ Open.

[5]  L. Smeeth,et al.  Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials , 2021, BMJ.

[6]  Sathish Kumar Jayapal,et al.  Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019 , 2020, Journal of the American College of Cardiology.

[7]  D. Francis,et al.  N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects. , 2020, The New England journal of medicine.

[8]  J. Pell,et al.  Comparison of Conventional Lipoprotein Tests and Apolipoproteins in the Prediction of Cardiovascular Disease , 2019, Circulation.

[9]  Daniel E Forman,et al.  2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2019, Journal of the American College of Cardiology.

[10]  John Fuller,et al.  Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials , 2019, The Lancet.

[11]  L. Goldstein,et al.  Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association , 2019, Arteriosclerosis, thrombosis, and vascular biology.

[12]  R. Collins,et al.  Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase , 2018, Yearbook of Paediatric Endocrinology.

[13]  D. Davis.  Statin Denial: An Internet-Driven Cult With Deadly Consequences , 2018, Annals of Internal Medicine.

[14]  S. Nissen.  Statin Denial: An Internet-Driven Cult With Deadly Consequences , 2017, Annals of Internal Medicine.

[15]  Peter Sandercock,et al.  Interpretation of the evidence for the efficacy and safety of statin therapy , 2016, The Lancet.

[16]  J. Tobert,et al.  The nocebo effect in the context of statin intolerance. , 2016, Journal of clinical lipidology.

[17]  A. Keech,et al.  Protocol for analyses of adverse event data from randomized controlled trials of statin therapy , 2016, American heart journal.

[18]  C. Ballantyne,et al.  Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. , 2016, JAMA.

[19]  S. Yusuf,et al.  Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. , 2016, The New England journal of medicine.

[20]  C. Cannon,et al.  Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. , 2015, Journal of clinical lipidology.

[21]  Barry J. Davis,et al.  Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials , 2015, The Lancet.

[22]  P. Thompson,et al.  A systematic review of statin-induced muscle problems in clinical trials. , 2014, American heart journal.

[23]  N. Jewell,et al.  Should people at low risk of cardiovascular disease take a statin? , 2013, BMJ.

[24]  R. Collins,et al.  The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials , 2012, The Lancet.

[25]  Suzanne G. Leveille,et al.  Statin use and musculoskeletal pain among adults with and without arthritis. , 2012, The American journal of medicine.

[26]  R. Collins,et al.  Prevention of Coronary and Stroke Events with Atorvastatin in Hypertensive Patients who have Average or Lower-than-Average Cholesterol Concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial— Lipid Lowering Arm (ASCOT-LLA): A Multicentre Randomised Controlled Trial , 2012, Drugs.

[27]  R. Collins,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.

[28]  R. Collins,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.

[29]  R. Collins,et al.  Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial , 2010, The Lancet.

[30]  Gert Mayer,et al.  Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. , 2009, The New England journal of medicine.

[31]  M. Clearfield.  Rosuvastatin in older patients with systolic heart failure. , 2009, Current atherosclerosis reports.

[32]  P. Libby,et al.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.

[33]  S. Feasson,et al.  MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals : a randomised placebo-controlled trial. , 2008 .

[34]  L. Tavazzi,et al.  Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. , 2008, Lancet.

[35]  J. Farmer.  High-dose atorvastatin after stroke or transient ischemic attack. , 2007, Current atherosclerosis reports.

[36]  D. Mikhailidis,et al.  Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes: The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN) , 2006, Diabetes Care.

[37]  M. Hennerici,et al.  High-dose atorvastatin after stroke or transient ischemic attack. , 2006, The New England journal of medicine.

[38]  S. Pocock,et al.  Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes , 2006, Diabetes Care.

[39]  E. Bruckert,et al.  Mild to Moderate Muscular Symptoms with High-Dosage Statin Therapy in Hyperlipidemic Patients —The PRIMO Study , 2005, Cardiovascular Drugs and Therapy.

[40]  W. März,et al.  Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. , 2005, The New England journal of medicine.

[41]  Philip J. Barter,et al.  Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.

[42]  M. Pfeffer,et al.  Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. , 2004, JAMA.

[43]  John H Fuller,et al.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.

[44]  Christopher P Cannon,et al.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[45]  I. Holme,et al.  Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial , 2003, The Lancet.

[46]  P. Macfarlane,et al.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.

[47]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[48]  P. Serruys,et al.  Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.

[49]  R. Collins,et al.  Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials , 2001, The Lancet.

[50]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[51]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[52]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[53]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[54]  Scandinavian Simvastatin Survival Study Group.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.

[55]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[56]  P. Armitage,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. , 1976, British Journal of Cancer.